Results 61 to 70 of about 4,245 (206)

Improvement strategies for peptide receptor scintigraphy and radionuclide therapy

, 2008
Somatostatin receptor-targeting peptides are widely used for the imaging and therapy of neuroendocrine tumors. Peptide-receptor radionuclide therapy (PRRT) in neuroendocrine tumor patients with radiolabeled somatostatin analogs has resulted in ...
Visser, Martijn, Jong, Marion, Verwijnen, SM   +2 more
core   +1 more source

A Biochemically “Silent” Aortocaval Paraganglioma in a 19‐Year‐Old Female Causing Intraoperative Hypertensive Crisis: A Rare Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Paragangliomas may appear biochemically silent, yet still behave as functional tumors with severe intraoperative consequences. Normal preoperative catecholamine screening does not exclude the risk of hypertensive crisis during surgery.
Abdul Basit, Tooba Yaqoob, Eyman Farrukh, Abdullah Iftikhar, Muhammad Usman Ali Khan, Majeed Haq   +5 more
wiley   +1 more source

Peptide Receptor Radionuclide Therapy & Oncology [PDF]

, 2017
Neuroendocrine tumors (NETs) are rare neoplasms with differences in clinical presentation, course and prognosis. Most of the NETs express the somatostatine receptor, which can be utilized for imaging and therapy.
Bergsma, H. (Hendrik)
core  

Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Challenge and Case Report

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Primary neuroendocrine carcinoma of the breast (NECB) represents an exceedingly rare entity, comprising less than 0.5% of all breast carcinomas and approximately 1% of all neuroendocrine neoplasms. The 2019 WHO classification defines NECB as tumors expressing neuroendocrine markers in > 90% of tumor cells with morphological features
Hamid Zeinali Nezhad, Shima Yaghoobi, Nazanin Zeinali Nezhad, Amirhossein Shahpar, Abtin Malekpour Afshar, Mina Bagherijamebozorgi   +5 more
wiley   +1 more source

ENETS concensus guidelines for the standards of care in Neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs

, 2009
The purpose of this guideline is to assist physicians caring for patients with neuroendocrine tumors in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT), and in defining the minimum requirements for PRRT.
Komminoth, P, European-Neuroendocrine-Tumor, Society, Kos-Kudla, B, de Herder, WW, Mallorca-Consensus-Conference, Participants, Lebtahi, R, Krenning, Eric, Kwekkeboom, DJ, de Herder, W.W., Krenning, EP, Plöckinger, U, Kwekkeboom, Dik   +11 more
core   +1 more source

Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response [PDF]

, 2021
Patients with neuroendocrine tumors (NETs) can be treated with peptide receptor radionuclide therapy (PRRT). Here, the somatostatin analogue octreotate radiolabeled with lutetium-177 is targeted to NET cells by binding to the somatostatin receptor ...
Chicco, D, Verkaik, Nicole, Haeck, Joost, Angotti, C, Nonnekens, Julie; id_orcid, Feijtel, Danny, Konijnenberg, Mark, Doeswijk, Gabriela, Jong, Marion, Nonnekens, Julie   +9 more
core   +1 more source

Phosphohistone H3 and Ki‐67 as prognostic markers in metastatic small intestinal neuroendocrine tumours: A comparative, retrospective cohort study

Journal of Neuroendocrinology, Volume 38, Issue 5, May 2026.
Abstract Ki‐67 index and mitotic count form the basis of grading of small intestinal neuroendocrine tumours (siNET). We hypothesized that the mitosis‐specific marker phosphohistone H3 (PHH3) might better correlate with cancer‐specific survival (CSS) and with response to treatment. We evaluated the association between Ki‐67 index, PHH3‐estimated mitotic
Dimitrios Papantoniou, Malin Grönberg, Eva Tiensuu Janson   +2 more
wiley   +1 more source

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients

, 2021
Peptide receptor radionuclide therapy (PRRT) is a well-established treatment in somatostatin receptor-expressing neuroendocrine tumours (NETs). The safety and efficacy of PRRT in >79 years old patients (EP) have not been systematically investigated ...
Marco Cattaneo, Guillaume P. Nicolas, Lawrence O. Dierickx, Peter Igaz, Deborah Theiler, Emanuel Christ, Simona Grozinsky-Glasberg, Claire Bournaud, M. Sue O’Dorisio, Damian Wild, Thomas O’Dorisio   +10 more
core   +1 more source

A case of renal primary neuroendocrine tumor (G3) in which 177Lu-PRRT was effective for disease control

Urology Case Reports
Primary renal neuroendocrine tumor (NET) is extremely rare, with no established treatment for advanced cases. We report high-grade (G3) renal NET effectively treated with peptide receptor radionuclide therapy (PRRT).
Saki Inaba, Toshiki Kijima, Mina Takaoka, Toshitaka Uematsu, Kohei Takei, Masahiro Yashi, Kazuyuki Ishida, Taku Aoki, Takao Kamai   +8 more
doaj   +1 more source

177Lu-DOTATATE therapy in metastatic/ inoperable pheochromocytoma-paraganglioma

Endocrine Connections, 2020
Introduction: 177Lu-DOTATATE-based peptide receptor radionuclide therapy (PRRT) is a promising therapy for metastatic and/or inoperable pheochromocytoma and paraganglioma (PPGL).
Sanjeet Kumar Jaiswal, Vijaya Sarathi, Saba Samad Memon, Robin Garg, Gaurav Malhotra, Priyanka Verma, Ravikumar Shah, Manjeet Kaur Sehemby, Virendra A Patil, Swati Jadhav, Anurag Ranjan Lila, Nalini S Shah, Tushar R Bandgar   +12 more
doaj   +1 more source